https://www.selleckchem.com/products/MK-1775.html
No standard of care exists for patients with high-risk biochemical recurrence (BCR) after prostatectomy. To evaluate whether addition of docetaxel to androgen deprivation therapy (ADT) improved progression-free survival (PFS) in high-risk BCR patients. TAX3503 was a multicenter phase 3 trial that randomized patients with high-risk BCR to ADT for 18 mo±docetaxel (75mg/m q3w for ten cycles). Eligibility included prostate-specific antigen (PSA) ≥1.0ng/ml after prostatectomy alone or after postoperative radiation therapy, PSA doubling time
Like
Comment
Share
